New biosimilar aims to rival cosentyx for psoriasis
NCT ID NCT06630559
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether CT-P55, a biosimilar of secukinumab, works as well as the approved drug Cosentyx for moderate to severe plaque psoriasis. 153 adults with chronic psoriasis for at least 6 months are receiving either CT-P55 or Cosentyx injections. The main goal is to see how much their psoriasis improves over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CT-P55 (a biosimilar of secukinumab)
- What this could lead to
- If it works, this could provide a more affordable treatment option for people with moderate to severe plaque psoriasis.
- What could go wrong
- This is a biosimilar, so it may not be as effective or safe as the original drug. The trial is relatively small (153 people) and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rheumatology Clinic NZOZ Lecznica MAK-MED s.c.
Nadarzyn, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection clear psoriasis when other biologics fail?
- Can a gel tame psoriasis? new antibody fragment put to the test
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a new drug called ZP9830 calm psoriasis Flare-Ups?
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.
- New oral pill TLL018 aims to clear psoriasis plaques in phase 2 trial